Actively Recruiting
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-23
50
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on \[68Ga\]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression. Utilizing whole-body PET technology, the pharmacokinetic dynamics of \[68Ga\]B7H3 Affibody-BCH are examined to ascertain its pharmacological characteristics. Ultimately, this research establishes a framework for pharmacokinetic analysis using whole-body PET.
CONDITIONS
Official Title
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years, male or female
- White blood cell count at least 4.0 x 10^9/L or neutrophils at least 1.5 x 10^9/L
- Platelets at least 100 x 10^9/L
- Hemoglobin at least 90 g/L
- Prothrombin time or activated partial thromboplastin time no more than 1.5 times the upper normal limit
- Total bilirubin no more than 1.5 times the upper threshold limit
- ALT and AST no more than 2.5 times the upper normal limit or no more than 5 times for those with liver metastasis
- Alkaline phosphatase no more than 2.5 times the upper normal limit or no more than 4.5 times in cases of bone or liver metastasis
- Blood urea nitrogen no more than 1.5 times the upper threshold limit
- Serum creatinine no more than 1.5 times the upper threshold limit
- Normal cardiac function
- Expected survival of at least 12 weeks
- Good adherence to follow-up
- At least one measurable target lesion according to RECIST 1.1 criteria
- Women of childbearing age (15-49 years) must have a negative pregnancy test within seven days before starting the study
- Sexually active male and female participants must agree to use effective contraception during the study and for three months after the last examination
- Clinical recommendation for PET/CT scans for tumor diagnosis and staging
- Ability to understand and voluntarily agree to participate and sign informed consent
You will not qualify if you...
- Severe abnormalities in liver and kidney function and blood counts
- Planning to conceive
- Pregnant or breastfeeding women
- Unable to lie flat for thirty minutes
- Refusal to participate in the clinical study
- Claustrophobia or other psychiatric disorders
- Other conditions deemed unsuitable for trial participation by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangxi Meng
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here